Protocol Ledger

NCT06706622 · Phase III · ACTIVE NOT RECRUITING

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

Interventional Phase III clinical trial protocol NCT06706622 sponsored by H. Lundbeck in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-03 Enrollment: 401 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06706622
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)401 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06706622
Protocol FieldVerified Registry Value
NCT IdentifierNCT06706622
Consolidated Lead SponsorH. Lundbeck
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment401 participants (ACTUAL)
Registered Start Date2024-12-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI